ライフサイエンスコーパス: percutaneous

1 o 0.70]; P<0.001) but a similar frequency of percutaneous access procedures per year.

2 $4274]; P<0.001), whereas the annual cost of percutaneous access procedures was similar in both group

3 iteal Lesions With A Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon), 300 symptomatic patie

4 rdial resection through a minimally invasive percutaneous approach mitigates the elevation in LV fill

5 A percutaneous approach with transcatheter aortic valve re

6 mber pacemakers implanted by using a femoral percutaneous approach.

7 For these patients, new percutaneous approaches are becoming available but no lo

8 doscopic drainage (640 events) and 12.3% for percutaneous biliary drainage (208 events) (P < .001).

9 ause of biochemical progression underwent 14 percutaneous biopsies after diagnostic PET/CT using (89)

10 The need for surgery if percutaneous biopsy of the breast after neoadjuvant chem

11 A percutaneous biopsy of the mass and bone marrow biopsy c

12 Percutaneous closure of prosthetic mitral valve paravalv

13 anted with the AMPLATZER Septal Occluder for percutaneous closure of secundum atrial septal defects.

14 Percutaneous coagulation of a post-pancreatitis pseudoan

15 ears) were prospectively included to undergo percutaneous computed tomographic-guided IRE.

16 In patients with NSTEMI, percutaneous coronary intervention </=72 hours from admi

17 multivessel coronary artery disease: 1-stage percutaneous coronary intervention (1S-PCI) during the i

18 hock (24%), mechanical support (28%), urgent percutaneous coronary intervention (28%), urgent coronar

19 coronary angiography (14.7% vs. 10.1%), and percutaneous coronary intervention (3.8% vs. 2.1%); all

20 y Intervention) for coronary angiography and percutaneous coronary intervention (667,424 procedures p

21 during the index procedure versus multistage percutaneous coronary intervention (MS-PCI) complete cor

22 comparing immediate/single-stage multivessel percutaneous coronary intervention (MV-PCI) versus culpr

23 First patients with STEMI undergoing primary percutaneous coronary intervention (n=1604; mean age, 61

24 ritising immediate revascularisation through percutaneous coronary intervention (or fibrinolysis), ad

25 r in the ratio of native versus graft vessel percutaneous coronary intervention (P=0.899), or regardi

26 ute myocardial infarction who are undergoing percutaneous coronary intervention (PCI) according to cu

27 dial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI) and deferred st

28 ry (AKI) remains a common complication after percutaneous coronary intervention (PCI) and is associat

29 and predictors of its improvement after CTO percutaneous coronary intervention (PCI) are unknown.

30 risk-adjusted 30-day readmission rates after percutaneous coronary intervention (PCI) as a pilot proj

31 There are concerns whether percutaneous coronary intervention (PCI) at centers with

32 hs of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) based on the pr

33 er coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) carries benefit

34 Previous studies found that percutaneous coronary intervention (PCI) does not improv

35 To examine access to reperfusion and percutaneous coronary intervention (PCI) during STEMI us

36 and predictors of long-term mortality after percutaneous coronary intervention (PCI) for radiation-a

37 t ischemic and bleeding events after primary percutaneous coronary intervention (PCI) for ST-segment

38 Thrombus aspiration during percutaneous coronary intervention (PCI) for the treatme

39 c versus nondiabetic patients after elective percutaneous coronary intervention (PCI) has not been re

40 herapy, optimal antiplatelet management with percutaneous coronary intervention (PCI) has not been we

41 larization of the culprit artery by means of percutaneous coronary intervention (PCI) improves outcom

42 y artery bypass grafting (CABG) surgery over percutaneous coronary intervention (PCI) in diabetic pat

43 Symptomatic relief is the primary goal of percutaneous coronary intervention (PCI) in stable angin

44 erns in anticoagulant strategies used during percutaneous coronary intervention (PCI) in the United S

45 among black and white patients treated with percutaneous coronary intervention (PCI) in the Veterans

46 postconditioning of the heart during primary percutaneous coronary intervention (PCI) induced by repe

47 Acute kidney injury (AKI) after percutaneous coronary intervention (PCI) is common, morb

48 Percutaneous coronary intervention (PCI) is most commonl

49 if coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) may offer a sur

50 Primary percutaneous coronary intervention (PCI) may therefore b

51 Percutaneous coronary intervention (PCI) of saphenous ve

52 catheter aortic valve replacement (TAVR) and percutaneous coronary intervention (PCI) of the left mai

53 association of short-term readmissions after percutaneous coronary intervention (PCI) on healthcare c

54 Public reporting of percutaneous coronary intervention (PCI) outcomes may cr

55 commended minimum number to an average of 50 percutaneous coronary intervention (PCI) procedures perf

56 etween procedural volume and prognosis after percutaneous coronary intervention (PCI) remains uncerta

57 cardiac stress testing within 2 years after percutaneous coronary intervention (PCI) to be rarely ap

58 on myocardial infarction (STEMI), the use of percutaneous coronary intervention (PCI) to restore bloo

59 with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) using everolimu

60 algorithm for chronic total occlusion (CTO) percutaneous coronary intervention (PCI) was developed t

61 TAVR was performed in the same setting if percutaneous coronary intervention (PCI) was uncomplicat

62 Percutaneous coronary intervention (PCI) with a bioresor

63 low reserve (FFR) measured immediately after percutaneous coronary intervention (PCI) with drug-eluti

64 However, some studies suggest that percutaneous coronary intervention (PCI) with drug-eluti

65 ry bypass graft (CABG) surgery compared with percutaneous coronary intervention (PCI) with drug-eluti

66 The comparative effectiveness of percutaneous coronary intervention (PCI) with drug-eluti

67 The SYNTAX [Synergy Between percutaneous coronary intervention (PCI) With Taxus and

68 Patients receiving primary percutaneous coronary intervention (PCI) within 90 min l

69 unprotected left main coronary artery (LMCA) percutaneous coronary intervention (PCI), but the overal

70 pecific outcome data for procedures, such as percutaneous coronary intervention (PCI), can influence

71 ine recommendations that patients undergoing percutaneous coronary intervention (PCI), coronary arter

72 dney injury (AKI) is common during high-risk percutaneous coronary intervention (PCI), particularly i

73 safety of the same-day discharge (SDD) after percutaneous coronary intervention (PCI), uptake of this

74 ociation with increased adverse events after percutaneous coronary intervention (PCI).

75 nefit (score >/=2) from prolonged DAPT after percutaneous coronary intervention (PCI).

76 ronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI).

77 , is approved for use in patients undergoing percutaneous coronary intervention (PCI).

78 e the shortcomings of drug-eluting stents in percutaneous coronary intervention (PCI).

79 for women and minorities after contemporary percutaneous coronary intervention (PCI).

80 40 STEMI patients reperfused by primary percutaneous coronary intervention (PPCI) underwent a CM

81 eft ventricular systolic function is primary percutaneous coronary intervention (PPCI).

82 gistry adopting the hybrid algorithm for CTO percutaneous coronary intervention (Registry of CrossBos

83 rel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI] [CHAMPION PHOEN

84 e potential to improve long-term outcomes of percutaneous coronary intervention after their complete

85 APT Study (Dual Antiplatelet Therapy), after percutaneous coronary intervention and 12 months of thie

86 Percutaneous coronary intervention and CABG show compara

87 Percutaneous coronary intervention and CABG were associa

88 rates of adverse cardiovascular events after percutaneous coronary intervention and may additionally

89 years or older, who were undergoing primary percutaneous coronary intervention and presenting less t

90 Local treatment of vulnerable plaques by percutaneous coronary intervention and systemic treatmen

91 Older patients treated with percutaneous coronary intervention are at increased risk

92 luting stents among 1919 patients undergoing percutaneous coronary intervention at 76 centers.

93 Percutaneous coronary intervention at a VA hospital.

94 S versus metallic EES in patients undergoing percutaneous coronary intervention at longest available

95 udied 17 903 consecutive patients undergoing percutaneous coronary intervention between 2000 and 2014

96 rest in New York were less likely to undergo percutaneous coronary intervention compared with referen

97 myocardial infarction patients treated with percutaneous coronary intervention discharged alive on A

98 ith stable coronary artery disease underwent percutaneous coronary intervention for a culprit lesion,

99 cluded in the study were patients undergoing percutaneous coronary intervention for myocardial infarc

100 educed bleeding and mortality during primary percutaneous coronary intervention for ST-segment elevat

101 foration (CP) during chronic total occlusion percutaneous coronary intervention for stable angina (CT

102 and Wales in 448 853 patients who underwent percutaneous coronary intervention from 2005 to 2012.

103 with STEMI undergoing transport for primary percutaneous coronary intervention from March 10, 2010,

104 ohort and validated in patients treated with percutaneous coronary intervention from the PLATelet inh

105 For relief of coronary obstruction, percutaneous coronary intervention has become a standard

106 Now marking its 40th anniversary, percutaneous coronary intervention has become one of the

107 y angioplasty on Sept 16, 1977, the field of percutaneous coronary intervention has evolved rapidly.

108 e in patients undergoing elective and urgent percutaneous coronary intervention in 90 hospitals in 13

109 BC is an independent predictor of MACE after percutaneous coronary intervention in a contemporary all

110 atients aged at least 18 years who underwent percutaneous coronary intervention in a lesion and had a

111 ed trials (TAPAS [Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Myocardial I

112 of restenosis, permitting widespread use of percutaneous coronary intervention in more advanced and

113 r coronary perforation (CP) occurring during percutaneous coronary intervention in patients with a hi

114 between culprit artery-only and multivessel percutaneous coronary intervention in patients with ST-s

115 eration DES, and bare-metal stents (BMS) for percutaneous coronary intervention in saphenous vein gra

116 all-comers population of patients undergoing percutaneous coronary intervention in the contemporary e

117 ients Registry), 4222 patients who underwent percutaneous coronary intervention in the United States

118 At the acute stage, intended primary percutaneous coronary intervention increased from 12% (1

119 fTRA CTO percutaneous coronary intervention is a valid alternativ

120 d not occur in isolation, and the success of percutaneous coronary intervention is also due to import

121 Percutaneous coronary intervention is associated with lo

122 heral revascularization is extrapolated from percutaneous coronary intervention literature.

123 METHODS AND We reviewed the 10-year percutaneous coronary intervention morbidity and mortali

124 es the processes for conduct of an effective percutaneous coronary intervention morbidity and mortali

125 omplete revascularization or infarct-related percutaneous coronary intervention only.

126 th only 16.5% or 2.2% undergoing in-hospital percutaneous coronary intervention or coronary artery by

127 We assessed revascularization status by percutaneous coronary intervention or coronary artery by

128 was not associated with changes in rates of percutaneous coronary intervention or in-hospital mortal

129 cess nationally has led to worse outcomes in percutaneous coronary intervention procedures performed

130 METHODS AND We analyzed 1253 CTO percutaneous coronary intervention procedures performed

131 tive analysis of 235 250 transfemoral access percutaneous coronary intervention procedures was undert

132 One-fifth of MI patients treated with percutaneous coronary intervention report 1-year postdis

133 (Ad Hoc Percutaneous Coronary Intervention Study in Acute Corona

134 t in a complex patient population undergoing percutaneous coronary intervention suggests a new direct

135 oronary intervention (P=0.899), or regarding percutaneous coronary intervention target vessels; the m

136 less procedural complexity, shorter primary percutaneous coronary intervention time was associated w

137 Patients (n=15 003) underwent percutaneous coronary intervention to SVG in England and

138 aimed to assess clinical outcomes following percutaneous coronary intervention to SVG in patients re

139 METHODS AND Patients undergoing percutaneous coronary intervention to SVG in the United

140 ive conditional survival up to 10 years post-percutaneous coronary intervention was calculated.

141 atheterization was common (71% and 51%), but percutaneous coronary intervention was low (6.5% and 5.0

142 Percutaneous coronary intervention was performed in 235

143 Percutaneous coronary intervention was successful in onl

144 ECLS, coronary angiography, and percutaneous coronary intervention were performed, as ap

145 cardial infarction (MI) treated with primary percutaneous coronary intervention were randomized to pr

146 a and incomplete revascularization following percutaneous coronary intervention were randomized to ra

147 radial access as the default access site for percutaneous coronary intervention wherever possible in

148 e thrombotic lesions, and 46 (84%) of 55 had percutaneous coronary intervention with 2.7 +/- 2.0 sten

149 Sex differences in the outcomes after percutaneous coronary intervention with drug-eluting ste

150 30, 2016, on patients who underwent primary percutaneous coronary intervention with stents and were

151 The SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardia

152 (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardia

153 In the SYNTAX (Synergy Between Percutaneous Coronary Intervention With Taxus and Cardia

154 r and 30-day rates of ischemic events during percutaneous coronary intervention without an increase i

155 of clinical variables (male sex and previous percutaneous coronary intervention) and 4 biomarkers (mi

156 : 1) CathPCI (Diagnostic Catheterization and Percutaneous Coronary Intervention) for coronary angiogr

157 ents with Incomplete Revascularization after Percutaneous Coronary Intervention) trial, a clinical tr

158 rel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) were 3 randomized, d

159 any cause, repeat revascularization (CABG or percutaneous coronary intervention), or nonfatal myocard

160 ed definite AST (occurring </=24 hours after percutaneous coronary intervention).

161 ronary angiography, 12 183 (46.2%) underwent percutaneous coronary intervention, and 2832 (10.7%) und

162 In Myocardial Infarction flow grade <3 after percutaneous coronary intervention, and arterial blood l

163 ed as having previous myocardial infarction, percutaneous coronary intervention, and coronary artery

164 atio >1.25, expansion index >/=0.8, previous percutaneous coronary intervention, and higher level of

165 y attributable to fewer hospitalizations for percutaneous coronary intervention, angina, and stroke.

166 technique in hybrid chronic total occlusion percutaneous coronary intervention, especially when ante

167 seline Q waves and additionally into primary percutaneous coronary intervention, fibrinolysis, or no

168 le or unstable angina, previous multi-vessel percutaneous coronary intervention, or previous multi-ve

169 gina with incomplete revascularization after percutaneous coronary intervention, ranolazine's effect

170 brovascular event at least 1 year before the percutaneous coronary intervention, the efficacy and ble

171 low, once they survive the first month after percutaneous coronary intervention, their prognosis is c

172 STEMI who were being transported for primary percutaneous coronary intervention, treatment with bival

173 rdial infarction management involves primary percutaneous coronary intervention, with ongoing studies

174 an regions across the United States with 132 percutaneous coronary intervention-capable hospitals and

175 period, 10 730 patients were transported to percutaneous coronary intervention-capable hospitals, in

176 Overall, 2514 (21.2%) of percutaneous coronary intervention-treated patients stop

177 t-elevation myocardial infarction undergoing percutaneous coronary intervention.

178 ed risk of post-operative stroke compared to percutaneous coronary intervention.

179 measures of prognosis in patients undergoing percutaneous coronary intervention.

180 ble for bare metal in-stent restenosis after percutaneous coronary intervention.

181 ne") for a preference of bypass surgery over percutaneous coronary intervention.

182 l approach for chronic total occlusion (CTO) percutaneous coronary intervention.

183 ally beneficial ancillary therapy in primary percutaneous coronary intervention.

184 ngrelor was compared with clopidogrel during percutaneous coronary intervention.

185 coronary angiography with intent to undergo percutaneous coronary intervention.

186 e antiplatelet therapy in patients following percutaneous coronary intervention.

187 mprove the outcomes of patients treated with percutaneous coronary intervention.

188 underwent the desensitization after primary percutaneous coronary intervention.

189 race and sex among MI patients treated with percutaneous coronary intervention.

190 ety of BVS versus EES in patients undergoing percutaneous coronary intervention.

191 oninfarct-artery intervention during primary percutaneous coronary intervention.

192 ion myocardial infarction undergoing primary percutaneous coronary intervention.

193 coronary angiography with intent to perform percutaneous coronary intervention.

194 publicly reported mortality statistics after percutaneous coronary intervention.

195 t-elevation myocardial infarction undergoing percutaneous coronary intervention.

196 anatomy, hemodynamic instability, or failed percutaneous coronary intervention.

197 ent in a broad patient population undergoing percutaneous coronary intervention.

198 STEMI, whether or not they were treated with percutaneous coronary intervention.

199 of repeat revascularization procedures were percutaneous coronary interventions (94.2%), and this di

200 s have demonstrated relatively high rates of percutaneous coronary interventions (PCIs) classified as

201 The frequency of complex percutaneous coronary interventions (PCIs) has increased

202 CTCA), and assess the safety and efficacy of percutaneous coronary interventions (PCIs).

203 telet reactivity and clinical outcomes after percutaneous coronary interventions among subjects with

204 nts undergoing diagnostic catheterization or percutaneous coronary interventions were randomized in a

205 with a follow-up of >/=2 years investigating percutaneous coronary interventions with BVS versus EES.

206 coronary syndromes and for those undergoing percutaneous coronary interventions.

207 resonance between 2 and 5 days after primary percutaneous coronary interventions.

208 ial infarction patients treated with primary percutaneous coronary interventions.

209 myocardial infarction in the era of primary percutaneous coronary interventions.

210 n myocardial infarction treated with primary percutaneous coronary interventions.

211 tricular arrhythmias (VAs) were subjected to percutaneous coronary occlusion to induce myocardial inf

212 In patients undergoing percutaneous coronary procedures, statin administration

213 e in the frequency of postoperative imaging, percutaneous drain placement, reoperation, readmission,

214 lication, any complication, reoperation, and percutaneous drainage (all P < 0.05).

215 ted by block randomization to receive either percutaneous drainage of lacrimal sac abscess followed b

216 t with EN-DCR as a secondary treatment after percutaneous drainage of lacrimal sac abscess in acute d

217 ions (incisional and organ space infections, percutaneous drainage procedures, unplanned reoperation,

218 Most pseudocysts were managed by percutaneous drainage, and although no firm inference ca

219 adiation bed seroma, which required periodic percutaneous drainage.

220 Thus, in addition to percutaneous drug delivery, microneedles have been consi

221 hich was primarily designed for facilitating percutaneous drug delivery.

222 novative Health Solutions, IN, USA) delivers percutaneous electrical nerve field stimulation (PENFS)

223 onths later received a total of 36 implanted percutaneous electrodes in his right upper and lower arm

224 We hypothesised that gastric juice and percutaneous endoscopic gastrostomy (PEG) feeding device

225 Percutaneous endoscopic gastrostomy (PEG) is an effectiv

226 s for age, sex, study site, primary coronary percutaneous intervention (PCI), and norepinephrine dose

227 metabolic Intervention as Adjunct to Primary Percutaneous Intervention in ST Elevation Myocardial Inf

228 femoral access for coronary angiography and percutaneous intervention, and collected fluoroscopy tim

229 in patients with cIAI requiring surgical or percutaneous intervention.

230 e of patients with congenital heart disease, percutaneous interventional treatments have supplanted m

231 ed, without a decrease in emergency surgery, percutaneous interventions, or admissions for diverticul

232 underwent three cycles of 10/10 min r-I/R by percutaneous intracoronary balloon inflation/deflation i

233 Conclusion Percutaneous IRE for locally advanced pancreatic cancer

234 Purpose To (a) investigate the safety of percutaneous irreversible electroporation (IRE) for loca

235 US-guided percutaneous irrigation of calcific tendinopathy (local

236 e-needle procedure when performing US-guided percutaneous irrigation of calcific tendinopathy is proc

237 ent outcomes for ultrasonography (US)-guided percutaneous irrigation of calcific tendinopathy.

238 omes, clinicians are increasingly turning to percutaneous left and right mechanical circulatory suppo

239 Over the past decade, percutaneous left atrial appendage closure has emerged a

240 artial hemodynamic support with a microaxial percutaneous left ventricular assist device (pLVAD) on r

241 dovascular aneurysm repair (n = 12633), or a percutaneous left ventricular assist device implant (n =

242 of this study was to determine whether a new percutaneous mechanical circulatory support (pMCS) devic

243 To review temporary percutaneous mechanical circulatory support devices for

244 Now, several percutaneous mechanical circulatory support devices, inc

245 ardiogenic shock, and hemodynamic effects of percutaneous mechanical circulatory support devices.

246 ng between or while managing patients with a percutaneous mechanical circulatory support devices.

247 rvational studies describing experience with percutaneous mechanical circulatory support in cardiogen

248 s are high, improvements and experience with percutaneous mechanical circulatory support may offer th

249 onducted with MeSH terms: cardiogenic shock, percutaneous mechanical circulatory support, extracorpor

250 re has been a substantial increase in use of percutaneous mechanical circulatory support.

251 rinolysis, ultrasound-assisted thrombolysis, percutaneous mechanical thrombus fragmentation, or percu

252 ikes delivered to the human median nerve via percutaneous microstimulation in four intact subjects an

253 (median diameter, 2.6 cm +/- 0.8) underwent percutaneous microwave ablation between March 2011 and J

254 Conclusion Percutaneous microwave ablation is an effective and safe

255 1a renal cell carcinomas (RCCs) treated with percutaneous microwave ablation.

256 el technological advancements have made this percutaneous minimally invasive therapy a first-line tre

257 examined consecutive patients who underwent percutaneous mitral PVL closure at Mayo Clinic, Rocheste

258 ge consecutive cohort of patients undergoing percutaneous mitral PVL closure, successful percutaneous

259 A total of 231 patients underwent percutaneous mitral PVL repair at a mean age of 67+/-12

260 This is a report of percutaneous mitral valve plication as a primary therapy

261 hrostograms to assess ureteral patency after percutaneous nephrolithotomy (PCNL) in this proof-of-con

262 as repeat biopsies subsequent to a previous percutaneous or bronchoscopic biopsy or previous surgica

263 incontinence include onabotulinumtoxinA and percutaneous or implanted neuromodulators.

264 Percutaneous or surgical ablation are increasingly used

265 aneous mechanical thrombus fragmentation, or percutaneous or surgical embolectomy-is best suited to a

266 any hemorrhage or hematoma, or the need for percutaneous or surgical intervention to control the ble

267 urinary tract drainage procedures (surgical, percutaneous, or endoscopic) were identified as protecti

268 women) at risk for infection due to sexual, percutaneous, or mucosal exposure; health care and publi

269 With chest intact in the pig model, percutaneous pericardial resection again blunted the inc

270 location of the main barrier of diffusion on percutaneous permeation.

271 This study examined the efficacy of percutaneous PFO closure as a therapy for migraine with

272 We hypothesized that percutaneous plication of the mitral valve could reduce

273 With the percutaneous procedure, the patient recovered uneventful

274 nic pancreatitis which was treated by direct percutaneous puncture of pseudoaneurysm and embolization

275 In addition, we elaborated on the choice of percutaneous puncture paths depending on the locations o

276 mited data exist on the impact of successful percutaneous PVL closure on midterm outcomes.

277 Mean time from mitral valve replacement to percutaneous PVL repair was 1.25 (0.31-7.25) years.

278 percutaneous mitral PVL closure, successful percutaneous reduction of the PVL to mild or less was as

279 The rates of percutaneous revascularization increased similarly at ou

280 In an era where a multitude of percutaneous solutions are emerging for the treatment of

281 (Percutaneous Stem Cell Injection Delivery Effects on Neo

282 The authors describe a first-in-human, fully percutaneous superior cavopulmonary anastomosis (bidirec

283 Percutaneous therapies for congenital heart disease have

284 Image-guided percutaneous thermal ablation has been one of the princi

285 Percutaneous thermal ablation should be considered an op

286 )-guided and computed tomography (CT)-guided percutaneous tissue sampling of lung nodules.

287 Transcaval access may enable fully percutaneous transcatheter aortic valve replacement (TAV

288 Bleeding complications after percutaneous transcatheter interventions that used large

289 A total of 100 patients underwent attempted percutaneous transcaval access to the abdominal aorta by

290 comes of all US patients undergoing elective percutaneous transfemoral TAVR between April 1, 2014, an

291 gnant biliary obstruction (MBO) treatment by percutaneous transhepatic biliary stenting (PTBS) with u

292 ires combination of indirect portography and percutaneous transhepatic portal techniques to increase

293 treatment with a low-dose DCB or an uncoated percutaneous transluminal angioplasty (PTA) balloon.

294 gned to DCB (n=200) or standard angioplasty (percutaneous transluminal angioplasty [PTA]) (n=100).

295 al coronary artery occlusion during elective percutaneous transluminal coronary angioplasty is associ

296 Revascularization with percutaneous transluminal renal angioplasty (PTRA) and s

297 (Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)

298 The SCOUT (Percutaneous Tricuspid Valve Annuloplasty System for Sym

299 Whereas the median number of percutaneous trocars (TVAE: 1 vs TGAE: 1; P < 0.450), th

300 ere performed in hybrid technique (median of percutaneous trocars: 1).